It was initially found that ibrutinib exhibited potent antitumor effect against non‐small cell lung cancer (NSCLC) cells, but only those with EGFR‐mutant (L858R or 19Del) (Grabinski and Ewald, 2014; Gao et al., 2014; He et al., 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.